As their first clinical data test looms, global AI player Insilico bumps up a GSK vet to co-CEO in charge of development
Days after topping up Insilico Medicine’s cash reserves with a $60 million round, the global AI player is redesigning its executive structure with an unusual twist as it shifts from pure drug design and discovery and builds out the pipeline with clinical stage assets.
A little more than a year after stepping in as the CSO, Feng Ren, the Harvard grad and GSK vet with experience in Philadelphia and Shanghai, is stepping up to a co-CEO role. He’ll be in charge of the development work, as they start testing more of their drugs in humans and put their promise of a more efficient approach to drug hunting to the ultimate test.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.